A Systematic and Ethnobotanical Review of Ashwagandha's ( Withania Somnifera ) Teratogenic and Abortifacient Potentials
Phytotherapy Research · 2026-08 · 40 (8) · 4737-4758
DOI: 10.1002/ptr.70079 ↗At a glance
Systematische Übersicht in Phytotherapy Research, published online on 2025-08-31. Written by Mark J Tallon and 2 co-authors. Institution: Legal Products Group Ltd, Ely, Cambridgeshire, UK. Major MEDLINE topics: Withania, Teratogens, Abortifacient Agents, Plant Extracts. Cited 4 times so far (Crossref); 99 references. The full text is freely available in PubMed Central.
Abstract (original language)
Withania somnifera (L.) Dunal, commonly known as ashwagandha, has been widely used in Ayurvedic medicine for its adaptogenic properties and therapeutic potential and has been investigated for its benefits related to sleep and stress management by Western medicine. However, concerns regarding its teratogenic and abortifacient effects have emerged following reports from the World Health Organization (WHO) and regulatory bodies. This systematic and ethnobotanical review critically evaluates these claims by assessing ashwagandha's toxicokinetics, toxicodynamics, and available safety data. A comprehensive literature review following PRISMA guidelines was conducted to identify studies on its reproductive toxicity, molecular interactions, and traditional usage. Historical ethnobotanical reports suggest potential abortifacient effects, but citation distortion and lack of primary source validation raise concerns regarding the validity of such claims. Toxicological studies in animal models demonstrate high tolerability, with no significant reproductive toxicity observed at doses relevant to human consumption. Human clinical studies also show no adverse effects on thyroid function, hormonal balance, or reproductive health. Altogether, evidence supporting significant teratogenic or abortifacient activity remains inconclusive. This review highlights the need for standardized, high‐quality research addressing fertility and developmental outcomes in controlled conditions. Given the widespread use of ashwagandha as a dietary supplement ingredient and traditional medicine, a balanced and evidence‐based approach is required to assess its safety, ensuring that regulatory actions are informed by robust scientific data rather than historical speculation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Legal Products Group Ltd, Ely, Cambridgeshire, UK.
- Department of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Center for Dietary Supplements Research, Fay W. Boozman College of Public Health, Univer…
- Product Safety Labs, Langone Health Grossman School of Medicine, Division of Environmental Medicine, New York City, New York, USA.
ORCID profiles: Mark J Tallon, Igor Koturbash
Cite
APA
Tallon, M. J., Koturbash, I., & Blum, J. L. (2026). A Systematic and Ethnobotanical Review of Ashwagandha's ( Withania Somnifera ) Teratogenic and Abortifacient Potentials. Phytotherapy Research, 40(8), 4737-4758. https://doi.org/10.1002/ptr.70079
Vancouver
Tallon MJ, Koturbash I, Blum JL. A Systematic and Ethnobotanical Review of Ashwagandha's ( Withania Somnifera ) Teratogenic and Abortifacient Potentials. Phytotherapy Research. 2026;40(8):4737-4758. doi:10.1002/ptr.70079
BibTeX
@article{Tallon2026,
author = {Tallon, Mark J and Koturbash, Igor and Blum, Jason L},
title = {A Systematic and Ethnobotanical Review of Ashwagandha's ( Withania Somnifera ) Teratogenic and Abortifacient Potentials},
journal = {Phytotherapy Research},
year = {2026},
volume = {40},
number = {8},
pages = {4737--4758},
doi = {10.1002/ptr.70079}
}
EUVIMED